Roivant Sciences' Q2 2026 Earnings Call Highlights: Brepocitinib and Batoclimab Show Promising Results in Dermatomyositis and Graves' Disease.

Roivant Sciences reported Q2 2026 earnings with a cash position of $4.4 billion and no debt. The company noted $500 million authorized for share repurchases and highlighted positive Phase III data for brepocitinib in dermatomyositis, with an NDA filing planned for the first half of 2026. Batoclimab showed sustained disease remission in Graves' disease patients, with reduced need for anti-thyroid drugs. The LNP litigation against Pfizer received a favorable Markman ruling, while a trial against Moderna is scheduled for March 2026.